

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: July 14, 2017	
Re.: Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated July 14, 2017, titled "Zydus receives Tentative Approval from the USFDA for Fingolimod Capsules".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **Cadila Healthcare Limited**


Open H. Shah
Company Secretary



Encl.: As above

Zydus receives Tentative Approval from the USFDA for Fingolimod Capsules

Ahmedabad, 14 July 2017

Zydus Cadila has received the tentative approval from the USFDA to market Fingolimod Capsules, 0.5 mg. The drug is an immunomodulating drug, mostly used for treating multiple sclerosis and will be produced at the group's formulations manufacturing facility at the Pharma SEZ, in Ahmedabad. The sales of Fingolimod Capsules is estimated at \$2.1 bn. Source: IMS Health, IMS National Sales Perspective Audit, MAT May 2017, extracted July 2017.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

###